Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Australian Household Spending Dips in December as RBA Tightens Policy 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche's CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisk’s controlling shareholder, Novo Holdings, from acquiring contract drug manufacturer Catalent. Schinecker voiced concerns about the potential negative impact on competition, particularly for smaller industry players. "While this doesn’t directly affect us, it could restrict options for smaller competitors if the number of available contract manufacturers decreases," he stated during a media call following Roche's quarterly sales report.
Consumer advocacy groups and labor unions recently petitioned the U.S. Federal Trade Commission (FTC) to intervene against the acquisition, citing risks to competition in the market for weight loss drugs and advanced gene therapies. They argued that the deal could limit opportunities for rivals like Amgen, Pfizer, Roche, and AstraZeneca, all of whom are developing obesity treatments, some based on complex peptides.
Other companies, such as Viking Therapeutics, Structure Therapeutics, and Sun Pharma, could also be impacted by this acquisition.
In contrast, Novo Holdings has defended its position, asserting a "pro-competitive rationale" for the deal. Teresa Graham, head of Roche's pharmaceutical division, reassured stakeholders that Roche is well-prepared, stating, "We have secured capacity with other contract manufacturing organizations and are confident in our production capabilities."
Roche plans to utilize a combination of in-house and external manufacturing for its forthcoming obesity drug launches, ensuring a steady supply chain.
